Aarti Pharmalabs quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	610	418	+45.9%
EBITDA	135	74.7	+80.9%
EBITDA margin	22.1%	17.9%	+4.3 pts
Profit before tax	88.1	39.3	+124.0%
Net profit	71.5	27.9	+156.0%
EPS	₹7.88	₹3.08	+155.8%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	610	536	583	432	418	386	564	538	458	555	506	449	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.5	0.5	8.1	−0.4	0.1	1.6	−1.6	5.0	4.5	2.2	2.0	1.4
	611	536	591	432	418	388	562	543	463	558	508	450
	335	252	226	209	203	191	185	261	221	220	202	215
	18.5	27.4	8.7	2.1	23.3	21.8	−16.3	7.9	98.1	86.9	59.9	38.5
	−54.4	−42.7	48.5	−38.9	−16.9	−43.8	110	6.3	−83.1	31.5	−8.3	−9.0
	54.5	50.3	45.0	43.4	43.4	41.3	43.4	41.6	37.7	39.2	37.4	36.2
	14.9	12.9	16.9	12.6	10.7	6.8	6.6	10.0	5.5	4.8	4.7	4.5
	30.5	30.0	28.2	28.6	24.8	22.8	22.8	23.0	20.9	20.2	19.1	18.8
	122	113	141	114	90.4	80.3	96.0	92.2	91.0	81.6	97.7	72.4
	521	443	515	371	379	321	448	442	391	484	412	376
	135	136	113	102	74.7	95.2	146	129	93.7	96.5	118	95.7
	105	106	85.0	73.7	49.9	72.5	123	106	72.8	76.3	98.4	76.9
Profit
	90.1	93.7	76.2	60.7	39.3	67.3	115	101	71.8	73.7	95.8	73.8
	−2.0	0.0	0.0	−2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	88.1	93.7	76.2	57.9	39.3	67.3	115	101	71.8	73.7	95.8	73.8
	20.1	20.1	18.1	9.3	2.2	12.6	16.9	22.0	14.4	14.2	13.9	14.4
	3.4	4.8	2.5	5.6	8.6	3.3	9.4	4.7	2.7	4.1	16.6	6.7
	23.5	24.9	20.6	14.9	10.8	16.0	26.3	26.6	17.1	18.2	30.5	21.1
	6.9	7.4	5.5	4.9	−0.6	−1.8	0.0	0.0	0.0	0.0	0.0	0.0
	71.5	76.1	61.1	48.0	27.9	49.5	88.3	74.0	54.6	55.5	65.3	52.8
	64.6	68.7	55.6	43.0	28.6	51.3	88.3	74.0	54.6	55.5	65.3	52.8
	−2.6	1.6	−4.9	−1.6	−0.8	1.0	−4.8	−2.7	−2.8	0.5	−0.9	0.3
	68.9	77.8	56.3	46.4	27.2	50.5	83.6	71.3	51.9	55.9	64.4	53.1
	68.9	76.1	61.1	46.4	28.6	—	—	74.0	54.6	55.5	64.4	52.8
Per share
	₹7.88	₹8.40	₹6.74	₹5.29	₹3.08	₹5.46	₹9.75	₹8.16	₹6.03	₹6.12	₹7.20	₹5.82
	₹7.87	₹8.39	₹6.74	₹5.29	₹3.08	₹5.46	₹9.74	₹8.16	₹6.02	₹6.12	₹7.20	₹5.82
Other comprehensive income — detail
	−2.6	1.6	−4.9	−1.6	−0.8	1.0	−4.8	—	—	—	—	—
	—	—	—	—	—	—	—	—	−2.8	—	—	—
	3.4	0.3	2.9	−0.1	−0.9	0.0	4.8	—	—	—	—	—
	—	—	—	—	—	—	—	0.9	0.0	0.0	0.0	—
	−0.8	−2.0	2.0	1.6	1.7	−1.0	0.0	—	—	—	—	—
	—	—	—	—	—	—	—	1.8	0.0	−0.5	0.9	—
	68.9	77.8	56.3	—	−0.8	—	—	71.3	—	55.9	64.4	52.8
Per share — as-filed variants
	₹7.88	₹8.40	₹6.74	₹5.29	₹3.08	₹5.46	₹9.75	₹8.16	₹6.03	₹6.12	₹7.20	₹5.82
	₹7.87	₹8.39	₹6.74	₹5.29	₹3.08	₹5.46	₹9.74	₹8.16	₹6.02	₹6.12	₹7.20	₹5.82
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	312	299	300	260	209	217	285	262	222	217	253	204
	51.0%	55.8%	51.4%	60.1%	49.9%	56.1%	50.6%	48.8%	48.6%	39.1%	50.0%	45.5%
Adjusted (ex-exceptional items) — derived
	90.1	93.7	76.2	60.7	39.3	67.3	115	101	71.8	73.7	95.8	73.8
	−2.0	0.0	0.0	−2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	73.0	76.1	61.1	50.0	27.9	49.5	88.3	74.0	54.6	55.5	65.3	52.8
	₹8.04	₹8.40	₹6.74	₹5.52	₹3.08	₹5.46	₹9.75	₹8.16	₹6.03	₹6.12	₹7.20	₹5.82

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIPHARM₹927.65

Aarti Pharmalabs Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAARTIDRUGS ADVENZYMES AGARWALEYE AKUMS ALIVUS APLLTD CORONA HCGMcap ₹8,410 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	448.7	505.8	555.5	458.0	537.8	563.8	386.2	418.3	432.3	582.6	535.8	610.5
Other Income	1.4	2.0	2.2	4.5	5.0	-1.6	1.6	0.1	-0.4	8.1	0.5	0.5
Total Income	450.1	507.8	557.7	462.5	542.8	562.2	387.8	418.4	431.9	590.7	536.2	610.9
Expenses
+ Cost of Materials Consumed	215.0	201.5	219.8	220.6	261.2	185.5	191.4	203.5	209.4	225.8	251.9	334.9
+ Purchases of Stock-in-Trade	38.5	59.9	86.9	98.1	7.9	-16.3	21.8	23.3	2.1	8.7	27.4	18.5
+ Changes in Inventories	-9.0	-8.3	31.5	-83.1	6.3	109.6	-43.8	-16.9	-38.9	48.5	-42.7	-54.4
+ Employee Benefit Expense	36.2	37.4	39.2	37.7	41.6	43.4	41.3	43.4	43.4	45.0	50.3	54.5
+ Finance Costs	4.5	4.7	4.8	5.5	10.0	6.6	6.8	10.7	12.6	16.9	12.9	14.9
+ Depreciation & Amortisation	18.8	19.1	20.2	20.9	23.0	22.8	22.8	24.8	28.6	28.2	30.0	30.5
+ Other Expenses	72.4	97.7	81.6	91.0	92.2	96.0	80.3	90.4	113.9	141.4	112.8	121.8
Total Expenses	376.3	412.0	484.0	390.7	442.2	447.5	320.5	379.1	371.2	514.5	442.6	520.8
EBITDA	95.7	117.5	96.5	93.7	128.6	145.6	95.2	74.7	102.3	113.1	136.1	135.2
EBIT	76.9	98.4	76.3	72.8	105.6	122.8	72.5	49.9	73.7	85.0	106.1	104.6
Profit
PBT before Exceptional Items	73.8	95.8	73.7	71.8	100.6	114.6	67.3	39.3	60.7	76.2	93.7	90.1
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8	0.0	0.0	-2.0
Pretax Income	73.8	95.8	73.7	71.8	100.6	114.6	67.3	39.3	57.9	76.2	93.7	88.1
+ Current Tax	14.4	13.9	14.2	14.4	22.0	16.9	12.6	2.2	9.3	18.1	20.1	20.1
+ Deferred Tax	6.7	16.6	4.1	2.7	4.7	9.4	3.3	8.6	5.6	2.5	4.8	3.4
Tax Expense	21.1	30.5	18.2	17.1	26.6	26.3	16.0	10.8	14.9	20.6	24.9	23.5
+ Share of Associates & JVs	0.0	0.0	0.0	0.0	0.0	0.0	-1.8	-0.6	4.9	5.5	7.4	6.9
Net Income	52.8	65.3	55.5	54.6	74.0	88.3	49.5	27.9	48.0	61.1	76.1	71.5
+ Net Income — Continuing Ops	52.8	65.3	55.5	54.6	74.0	88.3	51.3	28.6	43.0	55.6	68.7	64.6
+ Other Comprehensive Income	0.3	-0.9	0.5	-2.8	-2.7	-4.8	1.0	-0.8	-1.6	-4.9	1.6	-2.6
Total Comprehensive Income	53.1	64.4	55.9	51.9	71.3	83.6	50.5	27.2	46.4	56.3	77.8	68.9
Net Income to Common	52.8	64.4	55.5	54.6	74.0	—	—	28.6	46.4	61.1	76.1	68.9
Per Share
Basic EPS	5.82	7.20	6.12	6.03	8.16	9.75	5.46	3.08	5.29	6.74	8.40	7.88
Diluted EPS	5.82	7.20	6.12	6.02	8.16	9.74	5.46	3.08	5.29	6.74	8.39	7.87
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-4.8	1.0	-0.8	-1.6	-4.9	1.6	-2.6
+ Items NOT to be Reclassified to P&L	—	—	—	-2.8	—	—	—	—	—	—	—	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	4.8	0.0	-0.9	-0.1	2.9	0.3	3.4
+ Tax on Items NOT to be Reclassified — alt tag	—	0.0	0.0	0.0	0.9	—	—	—	—	—	—	—
+ Tax on Items to be Reclassified	—	—	—	—	—	0.0	-1.0	1.7	1.6	2.0	-2.0	-0.8
+ Tax on Items to be Reclassified — alt tag	—	0.9	-0.5	0.0	1.8	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	52.8	64.4	55.9	—	71.3	—	—	-0.8	—	56.3	77.8	68.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	5.82	7.20	6.12	6.03	8.16	9.75	5.46	3.08	5.29	6.74	8.40	7.88
Diluted EPS — Continuing Operations	5.82	7.20	6.12	6.02	8.16	9.74	5.46	3.08	5.29	6.74	8.39	7.87
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	204.3	252.7	217.3	222.4	262.5	285.0	216.8	208.6	259.6	299.6	299.2	311.5
Gross Margin %	45.52	49.95	39.11	48.57	48.81	50.56	56.13	49.85	60.06	51.42	55.84	51.03
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	73.8	95.8	73.7	71.8	100.6	114.6	67.3	39.3	60.7	76.2	93.7	90.1
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8	0.0	0.0	-2.0
Net Income Adj (tax-effected)	52.8	65.3	55.5	54.6	74.0	88.3	49.5	27.9	50.0	61.1	76.1	73.0
EPS Adj	5.82	7.20	6.12	6.03	8.16	9.75	5.46	3.08	5.52	6.74	8.40	8.04
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	45.3	45.3	45.3	45.3	45.3	45.3	45.3	45.3	45.3	45.3	45.3	45.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Aarti Pharmalabs Q2 FY27 results (July–September 2026)

Filed with NSE on Wednesday, 28 October 2026 at 9:02 pm IST

Aarti Pharmalabs (NSE: AARTIPHARM) reported its Q2 FY27 results (July–September 2026) on Wednesday, 28 October 2026 at 9:02 pm IST. Consolidated net profit attributable to shareholders was ₹68.9 crore, up 141.3% from ₹28.6 crore in Q2 FY26 and down 9.5% from ₹76.1 crore in Q1 FY27. Revenue from operations was ₹610 crore, up 45.9% year on year and up 13.9% from the previous quarter.

Q2 FY26 results (a year earlier): 9 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹68.9 Cr+141.3% vs Q2 FY26−9.5% vs Q1 FY27Total incl. minority interest ₹71.5 Cr
Revenue from operations: ₹610 Cr+45.9% vs Q2 FY26+13.9% vs Q1 FY27
Operating margin (EBIT): 17.1%+5.2 pts vs Q2 FY26−2.7 pts vs Q1 FY27EBIT ₹105 Cr
EBITDA: ₹135 Cr+80.9% vs Q2 FY26−0.7% vs Q1 FY27margin 22.1%
Earnings per share (basic): ₹7.88+155.8% vs Q2 FY26−6.2% vs Q1 FY27
Net profit margin: 11.3%+4.5 pts vs Q2 FY26−2.9 pts vs Q1 FY27

Questions

What was Aarti Pharmalabs' net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹68.9 crore, up 141.3% from ₹28.6 crore in Q2 FY26 and down 9.5% from ₹76.1 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹71.5 crore.

How were Aarti Pharmalabs' Q2 FY27 results?

Both grew from a year earlier: net profit was up 141.3% at ₹68.9 crore and revenue was up 45.9% at ₹610 crore. The operating margin was 17.1%, up 5.2 percentage points from 11.9% a year earlier. Against Q1 FY27, net profit was down 9.5% and revenue up 13.9%.

What was Aarti Pharmalabs' net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹145 crore, up 85.8% from ₹78.1 crore in the same months a year earlier. Revenue from operations was ₹1,146 crore, up 42.5%.

What was Aarti Pharmalabs' revenue in Q2 FY27?

Revenue from operations was ₹610 crore, up 45.9% year on year and up 13.9% from the previous quarter.

What was Aarti Pharmalabs' EPS in Q2 FY27?

Basic earnings per share were ₹7.88, against ₹3.08 in Q2 FY26.

When did Aarti Pharmalabs announce its Q2 FY27 results?

On Wednesday, 28 October 2026 at 9:02 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 9 November 2025.

What was Aarti Pharmalabs' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹105 crore, a margin of 17.1%, against 19.8% in Q1 FY27 and 11.9% in Q2 FY26. EBITDA was ₹135 crore, 22.1% of revenue.

What is Aarti Pharmalabs' net profit margin?

Aarti Pharmalabs' net profit margin was 11.3% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 6.8% in Q2 FY26 (up 4.5 percentage points). For FY26 as a whole it was 9.5%.

What was Aarti Pharmalabs' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹173 crore in FY26 (April 2025–March 2026), down 36.6% from ₹272 crore in FY25. It was ₹216 crore in FY24 and ₹193 crore in FY23: down 10.7% over three years, an average fall of 3.7% a year.

How has Aarti Pharmalabs' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹46.4 crore in Q3 FY26, ₹61.1 crore in Q4 FY26, ₹76.1 crore in Q1 FY27 and ₹68.9 crore in Q2 FY27. That is ₹253 crore over the four quarters, up 5.1% from ₹240 crore in the four quarters before. Revenue from operations: ₹432 crore, ₹583 crore, ₹536 crore and ₹610 crore.

What was Aarti Pharmalabs' revenue in FY26?

Revenue from operations was ₹1,819 crore in FY26 (April 2025–March 2026), down 14.0% from ₹2,115 crore in FY25. It was ₹1,853 crore in FY24 and ₹1,945 crore in FY23: down 6.5% over three years, an average fall of 2.2% a year.

When will Aarti Pharmalabs announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Aarti Pharmalabs figures come from?

From Aarti Pharmalabs' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 28 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.